Results 121 to 130 of about 38,595 (290)

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case–control study

Therapeutic Advances in Musculoskeletal Disease
Background: Obesity has been proposed as a risk factor for the development of rheumatoid arthritis (RA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight reduction and glycemic control and have been shown to ...
Ariel Israel, Fadi Hassan, Eugene Merzon, Jalal Kurtam, Jamal Awad, Mai Assalia, Ilan Green, Shlomo Vinker, Mohammad E. Naffaa   +8 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis

North American Spine Society Journal
: Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as potentially impactful agents in improving spinal fusion outcomes. While several recent studies have investigated the effect of these agents on lumbar spinal procedures ...
Christian Rajkovic, BS, Ankita Jain, MS, Mahnoor Shafi, MBBS, Oserekpamen Omobhude, BS, Tej Azad, MD, Austin Carpenter, MD, Timothy F. Witham, MD, Merritt D. Kinon, MD, John V. Wainwright, MD   +8 more
doaj   +1 more source

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin, Stella Talic, Harvey J. W. Koh, Arul Earnest, Anthony W. Russell, Sophia Zoungas   +5 more
wiley   +1 more source

A Clinical Practice Guideline for Managing Gastrointestinal Toxicities Related to GLP-1RA and GIP/GLP-1RA Medications

The project is a Clinical Practice Guideline (CPG) for managing Gastrointestinal (GI) toxicities related to Glucagon-like Peptide-Receptor Agonist 1 (GLP-1RA) and Glucose-dependent insulinotropic polypeptide/Glucagon-like peptide-1Receptor Agonist (GIP ...
Williamson, Lindsay
core  

Relative contributions of basal vs postprandial hyperglycaemia to overall glycaemic control in newly diagnosed Chinese adults with type 2 diabetes before and after 3 months' intensive glucose‐lowering therapy

Journal of Diabetes Investigation, EarlyView.
In newly‐diagnosed Chinese with T2D, Contribution of basal hyperglycaemia to hyperglycaemic exposure decreased substantially and the relative importance of postprandial hyperglycaemia increased markedly after 3 months glucose‐lowering therapy. Therapy should be re‐evaluated after initial treatment, and that a greater focus on limiting postprandial ...
Yixuan Sun, Yong Luo, Cong Xie, Karen L. Jones, Michael Horowitz, Christopher K. Rayner, Jianhua Ma, Tongzhi Wu   +7 more
wiley   +1 more source

GLP Online Fachforum – Erster Entwurf der GLP Bundesstelle zur Neufassung der ChemVwV-GLP

Der Vortrag stellt die ChemVwV-GLP und Gründe für die Aktualisierung vor, beschreibt die Beteiligung der Bundesländer, gibt eine Kurzvorstellung zu wesentlichen Änderungen des ChemVwV-GLP Entwurfs der GLP-Bundesstelle und stellt das heutige Programm mit ...
Strüh, Christian
core  

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease

Cardiovascular Diabetology
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D), yet remain underutilized ...
Ziad Arow, Tzipi Hornik-Lurie, Ranin Hilu, Ela Giladi, Yoav Arnson, Hana Vaknin-Assa, Abid Assali, David Pereg, For the CARDIAB research group   +8 more
doaj   +1 more source

The Role of GLP-1 Receptor Agonists in Eating Disorders: Appetite Regulation and Neurobiological Mechanisms

Neurologijos seminarai
Valgymo sutrikimai, tokie kaip nervinė anoreksija, nervinė bulimija ir persivalgymo sutrikimas, dažnai siejami su neurobiologinėmis disfunkcijomis, įskaitant dopamino ir atlygio sistemų pokyčius.
Julija Blažytė, Robertas Strumila
doaj   +1 more source

The glucagon-like Peptide-2 [PDF]

, 2011
Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like
Mule, Flava, MULE', Flavia
core